Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with oc...

Descripción completa

Detalles Bibliográficos
Autores principales: Colao, Annamaria, Bronstein, Marcello D, Brue, Thierry, De Marinis, Laura, Fleseriu, Maria, Guitelman, Mirtha, Raverot, Gerald, Shimon, Ilan, Fleck, Jürgen, Gupta, Pritam, Pedroncelli, Alberto M, Gadelha, Mônica R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222286/
https://www.ncbi.nlm.nih.gov/pubmed/32217809
http://dx.doi.org/10.1530/EJE-19-0762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222286/
https://www.ncbi.nlm.nih.gov/pubmed/32217809
http://dx.doi.org/10.1530/EJE-19-0762

Ejemplares similares